Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,105.40 | 5.70 | -0.06% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 24,996.78 | 86.15 | 0.35% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,149.02 | 354.16 | 0.87% |
| NZX 50 Index | 12,925.57 | 45.41 | 0.35% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,835.90 | 7.80 | -0.09% |
| SSE Composite Index | 3,638.39 | 4.39 | 0.12% |